ABSTRACT
INTRODUCTION
Aluminum (Al) is one of the most abundant metals in the earth's crust. Al and its salts aluminum chloride (AlCL3) are commonly used in daily life, mainly in food products and in drinking water [1] . nevertheless; the core mechanism of Al CL3 damaging effect still debated. Frontal cortex and hippocampus, the areas of the brain important for learning, memory and mood, are highly vulnerable to normal aging and AD [6] . Anti-inflammatory agent, cilostazol inhibits phosphodiesterase III with therapeutic focus on increasing cAMP that increases the active form of Protein Kinase A, which is directly related to inhibition of platelet aggregation [7] . In addition, it has been shown to inhibit lipid peroxidation, apoptosis and neuronal dysfunction in a model of cerebral ischaemia [8] . Moreover, cilostazol induced inhibition of inflammatory cytokine release from macrophages [9] and reduced the cell damage caused by oxidative stress [10] . However, the ameliorative effect of antiinflammatory agent, cilostazol on the learning and memory impairment has not been studied, and its mechanism is not yet clear.
Several antioxidants are used for therapy of neurodegenerative disorders. Antioxidant agent, N-acetyl cysteine (NAC) is precursor of glutathione that plays an essential role in oxidative damage [11] . Also, NAC could attenuate neuroinflammation [12] . Based on this finding, the current investigation was designed to evaluate the neuroprotective effect of NAC against aluminium-induced cognitive impairment.Transforming growth factor B (TGF-B) plays an important role in brain response to injurious factors [13] . Many studies reported increased TGF-B associated with reduction of brain derived neurotrophic factors (BDNF) in case of cortical dysfunction of AD patients [13] . AD is the most common form of dementia in elderly people. It affects more than 30 million people worldwide and the number of affected people expected to be double within the next 20 years [14] . Therefore, searching the pathophysiological mechanisms underlying in AD will be an attractive and necessary to identify efficacious strategies that can avoid AD. In this study, we used AlCL3 exposed rat as a model of AD to examine the pathophysiological mechanisms by which antiinflammatory agent (cilostazol) and antioxidant agent (NAC) exert their effects on learning and memory impairment in order to prove the predominant mechanism involved. Also, the study highlights on the relation between brain growth factors and cytokines and cognitive impairment. By using behavioral tests, biochemical assays and histological study, we compared the effects of anti-inflammatory agent on learning and memory impairment induced by AlCL3 with those of antioxidant agent.
MATERIAL & METHODS

Chemicals:
AlCL3, NAC and cilostazol were obtained from Aldrich Chemicals Co., Sigma Chemicals Co., (St Louis, MO, USA) and Pharmatic Biotech (Sweden) respectively. Their solutions were made freshly at the beginning of each experiment. For oral administration, AlCL3 was dissolved in distilled water (DW) while NAC and cilostazol were suspended in 0.5% carboxymethyl cellulose sodium salt (Aldrich Chemicals Co.).
Animals: Adult male albino rats weighing 100-150 g at the start of the study were used. They were disease free, obtained and maintained in the Assiut University Animal Nutrition and Care House, and were acclimatized to the laboratory conditions at room temperature before the experiments. The rats were housed in metal cages (5 /C) and they were allowed free access to rodent laboratory food and water throughout the experiment. The housing facility was maintained at 25 °C with a 12:00 h light, 12:00 h dark cycle and under a controlled humidity environment. The animals were carried out and all manipulations were done in the light phase between 09.00 a.m. and 04.00 p.m. The experimental protocol was approved by the Institutional Animal Research Committee of Faculty of Medicine, Assiut University, Egypt and was carried out in accordance with the published Guidelines and regulations for the use and care of animals.
Treatment protocols:
The animals were equally alienated into six groups of 10 animals each. In group I (control DW ), II (control antioxidant) and III (control anti-inflammatory), rats were given distilled water orally, 100 mg NAC/ kg -1 b.w./ day IP and 30 mg cilostazol /kg -1 b.w./ day orally respectively for 6 weeks. Animals of group IV (Alzheimer's model) were given AlCL3 (100 mg/kg -1 b.w.) through oral gavages for the same duration, while those of group V (Alzheimer's model + antioxidant) and group VI (Alzheimer's model + antiinflammatory) were given the same dose of NAC and cilostazol one hr before administration of AlCL3 for the same duration. The doses of aluminium chloride, NAC and cilostazol were selected on the basis of those reported in the literatures [15, 16 and 17 respectively] . AlCl3, NAC and cilostazol solutions were freshly prepared before administration. Drugs were given daily at 08:00 a.m. while behavioral tests were performed at 11:00 a.m.
Methods: Body weight:
All animals were weighed at the beginning (baseline) and at the end of the experiment (9 a.m.).
Learning and memory behavioral tests:
The ability to navigate and complete a maze task requires the ability to create and store a cognitive map, and AD affects the mechanisms by which visuospatial memory is formed and recalled spatial navigation task. The learning and memory tests were performed at day 0 (before start the experiment) and at day 1, 15 [19]. Each rat was placed in the illuminated compartment and 10 sec. later the door was raised and the latency (initial latency) to enter the dark compartment was noted and upon entry, the door was closed and a foot shock administered (0.3 m A, 3 s), using a shock generator-scrambler; Muromachi-kikai). Twenty-four hours after the training trial (day 1 of ALCL3 administration), the rat was again placed in the illuminated chamber and the latency was again noted up to a maximum of 300 sec. (Retention trial). The tests were carried out again at day 15, 30 and 45 of AlCL3 administration to record the onset of memory impairment. C-Eight-arm radial maze (index of hippocampus-dependent spatial memory). Four fixed arms were baited with food (cheese) in the food plastic cups. Four food pellets were placed just outside the unbaited arms to provide symmetrical food odor all around the maze. After the over night fasting, individual animals were placed in the central area of the maze, timing was begun and the rat was free to discover. Arm choices were recorded after the rat entered completely into the arm and the trial was judged completed when the rat had chosen all baited arms or had spent 10 min [20] . The following parameters were calculated:
working memory (the number of repeated entries to baited arms), reference memory (the number of entries to unbaited arms) and completion time (the mean latency required to complete the task).
Biochemical assays:
At the end of the experiment the rats were sacrificed by cervical dislocation, the hippocampus and frontal cortex were micro-dissected, washed in isotonic saline, and dried. Each brain sample was mid-sagittally divided into 2 portions. The first portion was fixed in formalin buffer for histopathological study. 
Data analysis:
Statistical analysis was carried out using Graph Pad Prism software (version 4.03). Data were analyzed non-parametrically (due to the small number of animals in the groups and the cut-off time of latency performance). First, to compare the difference within groups the Friedman analysis of variance (ANOVA) followed by Dunn's method was used. Second, to compare the differences between the control and other group, the Mann/Whitney U-test was used. The level of statistical significance was P < 0.05 for all statistical evaluations
RESULT PRESENTATIONS
Time course monitoring of learning and memory tests of control DW rats revealed that the mean latencies (in sec.) recorded by MWM ( Fig. 1 a) and the incidence of errors in both working and reference memory decreased significantly as well as the completion time shortened progressively from day 0 to day 45 (Fig. 2) . While retention latencies recorded by step-through passive avoidance at day 1 increased significantly relative to the results of day 0 (Fig. 2 b) . Also, biochemical assays of control DW group showed a significant (P < 0.001) increase the levels of LP, catalase, reducedglutathione, TGF-B, BDNF and TNF-α while decrease AChE (P < 0.05) in hippocampus relative to that of frontal area as shown in table 2 and  figures 3&4. In addition, histopathological study showed normal cellular structure of frontal cortex and hippocampus area (H&E x400) which confirms the establishing of normal working and reference memories (Fig. 5, 6 ). It was observed that administration of antioxidant or anti-inflammatory alone did not significantly influence any of the previous parameters compared to control DW rats.
1) Result of Alzheimer model:
A) On body weight, survival rate and learning and memory tests. Administration of AlCL3 for 45 day significantly reduced body weights, survival rate (table 1) at the end of experiment. Similarly, the latencies recorded by step-through passive avoidance decreased significantly after 15 days with progression until reached maximum at day 45 (figure 1 b). While, it induced a significant increase in the latencies recorded by MWM on day 30 and 45 ( Figure 1 a) , the number of errors among day 15, 30 and 45 in working memory and among day 30 and 45 in reference memory. Also, AlCL3 significantly increased the completion time started at day 30 (Fig. 2) . B) On oxidative biomarkers, ACh E activity, aluminium concentration, brain growth factors and inflammatory cytokine: Meanwhile, biochemical assays of frontal cortex and hippocampus of Alzheimer model rats revealed a significant increase of lipid peroxidation products, nitrite concentration (Fig.3) ; AChE activity, the aluminium concentration (Fig. 4) ; levels of pro-inflammatory cytokines (IL2 and TNF-α ) and TGF-B (table 2) relative to the control DW group. However, Alzheimer model group showed depletion of reduced glutathione levels, superoxide dismutase, catalase (Fig.3) and levels of BDNF (table 2) in both brain areas with obvious effects appeared in hippocampus area. C) On histopathological study: Gross histopathological changes in frontal cortex and hippocampus, including heavy loss of cortical neurons, lacunae spaces cells and vacuolated cytoplasm were observed in Alzheimer model rats (Fig. 5,6) . 2) Effect of application of antioxidant or anti-inflammatory on Alzheimer model rats: A) On body weight, survival rate and learning and memory tests.
Administration of antioxidant or anti-inflammatory increased significantly the survival rate (table  1) , latencies recorded by step-through passive avoidance (Fig. 1 b) at day 30 and 45 with better response in antiinflammatory group than antioxidant their percentage differences from control DW at day 45 were 56% and 60% respectively. However, both agents significantly lowered the latencies of MWM (figure 1a), the number of errors of working & reference memories and the completion time (Fig. 2) . Antiinflammatory agent has more amelioration effect than antioxidant and their percentage differences of latencies in MWM from control DW at day 45 were 188%, 239% respectively. The percentage differences from control of antiinflammatory and antioxidant groups in working, reference memories and completion time at day 45 were 169% &113%, 236% & 157% and 130% & 123% respectively. B) On oxidative biomarkers, AChE activity, aluminium concentration, brain growth factors and inflammatory cytokine.
Co-administration of antioxidant or anti-inflammatory agents significantly prohibited the changes in the previously measured parameters (figure 3 &4). The percent of differences of antioxidant & antiinflammatory from control DW levels were: (LP 123%, 146% and 106%, 124%), (nitrites 105%, 123% and 110%, 126%), (reduced glutathione 105%, 84% and 75%, 55%), (SOD 19%, 9% and 19%, 5%) and (Catalase 34%, 27% and 35%, 32%) in frontal cortex and hippocampus respectively. Similarly, treatment with antioxidant and anti-inflammatory agents significantly attenuated the AChE activity only in hippocampus area and declined the elevated concentration of AlCL3 in both brain areas. (Fig.4) . The percent of differences of ACh E from control, in antioxidant and antiinflammatory groups, were 123%, 149% in frontal cortex and 122.5%, 100% in hippocampus respectively while that for aluminum concentration were 110%, 103% in frontal cortex and 149%, 140% in hippocampus respectively.
Statistical analysis revealed that administration of antiinflammatory to Alzheimer's model rats reduced significantly the elevated levels of pro-inflammatory cytokines (IL2 and TNF-α ) and TGF-B while it increased levels of BDNF in hippocampus area only (table 2) . C) On histopathological study: Remarkable improvement was observed in the anti-inflammatory + Alzheimer's model and antioxidant + Alzheimer's model groups. Normalization of most of neuronal structure was observed after administration of anti-inflammatory agent ( Figure 5 ). Similar changes were observed in hippocampus (figure 6). 
Values represent means ± SEM (n =10). Alzheimer model was induced by AL CL3
(100 mg/kg-1 b.w per rat daily orally) for 45 days. Rats were pretreated with antioxidant (NAC) orally (Alzheimer's + antioxidant) or anti-inflammatory (cilostazol) 1hr. before AlCL3 for the same duration. All parameters were assessed at the end of experiment. Significant levels; *P< 0.05, ***P < 0.001 versus control DW (Student's t-test), # P <0.05,## P < 0.01, ### P <0.001 versus Alzheimer model group. %= percentage difference from control. 
DISCUSSION
In the current study, time course monitoring of memory and learning tests of control animals verifies the development of spatial learning and memory, however, active learning was significantly impaired in Alzheimer's model group which manifested by increasing latencies in MWM associated with increasing reentry frequency of the animals and prolongation of completion time in radial arm maze adding to shorten latencies to enter shocking compartment in passive avoidance. The recorded negative effects of AlCL3 on memory and learning functions, in the current study, concur with the results of Thirunavukkarasu et al., [30] . These findings harmonized with marked neuronal loss and vacuolated cytoplasm proofed by histopathological study of frontal cortex and hippocampus of Alzheimer's model rats. These results prove the success of orally administered 100 mg /kg AlCL3 to reach the brain and induce model of AD with cognitive dysfunction that manifested mostly after thirty days of AlCL3 exposure which is in concordance with the studies of Abdel-Aal et al., [31] who reported that AlCL3 is considered as a potential etiological factor in AD. This finding could be attributed to the ability of aluminium to interfere with cyclic GMP, involved in long-term potentiation and memory
[32] that could explain the recorded memory impairment.
Administration of antioxidant or antiinflammatory agents to Alzheimer's model animals induced a significant improvement of learning and memory tests with obvious response recorded after antiinflammatory application that goes in lines with the results of Lee et al., [33] . Anti-inflammatory and antioxidant agents began to improve the performance of the Alzheimer model rats at day 30, which verify their abilities to retain and retrieve information after treatment with both agents. Their amelioration effects on cognitive function supports by previous investigators
[34&35 ] . Antiinflammatory, cilostazol can protect against cognitive impairment induced by hypoperfusion in rats [37] . In the current study, Alzheimer's model showed a reduction in body weight and the number of living rats that were associated with deterioration of cognitive function. The physiologic explanation of this outcome may be contributed to the ability of AlCL3 to depress general brain function including appetite centre that runs parallel with suppression of cognitive function [38] . Neither the used antiinflammatory nor antioxidant agent can increase significantly the body weight however; they increased the suppressed survival rate.
Cholinergic neurons are positive markers for the progression of memory so disturbance of acetylcholine and ACh E activity may be one of the mediators of cognitive dysfunction in AD
[39] . AlCL3 has a biphasic effect on ACh E activity, with an initial increase in the activity of this enzyme followed by a marked decrease. This biphasic effect has been attributed to the accumulation of aluminium in the brain
[40] which coincides with the recorded elevation of AlCL3 concentration that parallel with increasing ACh E activity in frontal cortex and hippocampus areas in the current investigation. This finding may be explained by the easy access of AlCL3 to the brain via the specific high affinity receptors in the blood-brain barrier [41] . The results presented here showed that antiinflammatory and antioxidant agents were able to attenuate the increased concentration of aluminium and ACh E activity in both regions of the rats' brain.
The brain is an organ that is in particular more susceptible to peroxide damage. Beside, increased production of reactive oxygen species (ROS) as lipid peroxidation and nitrite concentration, as well as decreased the levels of antioxidant enzymes, in frontal cortex and hippocampus of Alzheimer's model group, may be a vital factor attributed to neuronal dysfunction. Thus, it can be hypothesized that oxidative stress could be one of the contributing factors for aluminum induced cognitive dysfunction. Interestingly, the oxidative changes were observed more in hippocampus than frontal cortex that agrees with its fundamental role in the recorded memory impairment. Brain imaging studies confirmed additionally that decreasing brain function in the hippocampus is a main contributor to decline in memory during old age and in AD
[6] . Moreover, Zhihao et al., [42] reported that AlCL3 is a potent prooxidant known to enhance lipid peroxides in hippocampus.
Because oxidative stress and cognitive dysfunction are closely related, agents that modulate reactive oxygen species may be potentially protective against impaired memory which is in accordance with the current results as administration of anti-inflammatory and antioxidant was found to improve not only the memory retention but also reduced oxidative damage induced in Alzheimer model. In the present work, antioxidant agent appears to be more potently attenuate the changes in oxidative biomarkers than antiinflammatory. In fact, antioxidant (NAC) is known to increase the intracellular stores of glutathione thereby enhancing the endogenous antioxidant level . The present data are in consistent with the results of the current study as anti-inflammatory treatment reduced the elevated levels of proinflammatory cytokines (IL 2 and TNF-α) especially in hippocampus while co-administration antioxidant, NAC with AlCL3 didn't improve significantly most of the measured proinflammatory cytokines. These results prove the superior role of anti-inflammatory agent which can explain the amelioration that happened in cognitive function and neuronal structure after its administration that harmonize with the findings of Choi et al., [10] and Kim et al., [9] . TGF-B plays a central role in brain response to injury and increases in AD [13] . Recommendation: The effects of both agents antioxidant (NAC) and anti-inflammatory, cilostazol need to be simulated in more physiological models of AD, and the involvement of additional molecular mechanism needs to be clarified as DNA fragmentation and an antiapoptotic effect. The shift to clinical trials using therapies that prevent inflammation and generate high levels of growth factors should be applied as they will eventually have a useful role in the treatment of AD. 
